Vodis Has Recieved A Permit To Operate Its Facility From The City Of Bellingham

2015-08-26 0500 PT - News Release

VP Close 2015-08-25 C$ 0.10

Mr. Otto Folprecht reports


August 26, 2015- Vancouver, British Columbia – Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV /Q:VDQSF) (“Vodis” or “the Company”) is pleased to announce that it has reached a significant milestone and received a permit to operate from the City of Bellingham.

The Company has received a permit to operate its facility as it has completed the installation of its air flow system and upgraded the plumbing and mechanical infrastructure.

Otto Folprecht, Vodis’ Chief Executive Officer, commented: “This is an important step for the Company and as it helps to take our tenant closer to production under Washington State i502 regulations.”

The Company’s facility is now ready for its i-502 tenant to undertake a traceability test of its BioTrackTHc Commercial System. Once the i-502 tenant passes its traceability test, Vodis will request an inspection of its facility from the Washington State Liquor and Cannabis Board (WSLCB).   In Washington State, it is expected that an inspection would occur after a request is provided to the WSLCB.


About Vodis

Vodis is one of Canada’s foremost brand names in the medical marijuana business. Its master grow teams have consistently won or placed at each competition they have entered with their “VIP” brand. The Company, with facilities in BC and Washington State, is also actively looking into expansion opportunities in other countries and US states.

For further information please contact:

Richard Schnoor

Head of Corporate Communications

Vodis Pharmaceuticals Inc.

8788 River Road

Delta, BC V4G 1B5

Direct: 1-866-210-1420 ext. 110

Web: www.vodis.ca


While Vodis Pharmaceuticals and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State license holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed the Vodis brand quality standards.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Forward-Looking Information:

This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. All of the forward-looking statements made in this news release and any accompanying graphic links are qualified by these cautionary statements and those in our continuous disclosure filings available on SEDAR at www.sedar.com. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.



Vodis Corporate

  • Page 1 of 71